Financial reports
ARS
2023 FY
Annual report to shareholders
15 Apr 24
10-K
2023 FY
Annual report
20 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Entry into a Material Definitive Agreement
18 Apr 24
8-K
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
20 Feb 24
8-K
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
14 Dec 23
8-K
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
2 Nov 23
8-K
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
11 Sep 23
8-K
Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
3 Aug 23
8-K
Entry into a Material Definitive Agreement
13 Jul 23
8-K
Departure of Directors or Certain Officers
23 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 23
8-K
Other Events
26 May 23
Registration and prospectus
S-8
Registration of securities for employees
20 Feb 24
424B5
Prospectus supplement for primary offering
13 Jul 23
424B5
Prospectus supplement for primary offering
12 Jul 23
424B5
Prospectus supplement for primary offering
26 May 23
S-3ASR
Automatic shelf registration
26 May 23
S-8
Registration of securities for employees
28 Feb 23
S-8
Registration of securities for employees
1 Mar 22
424B5
Prospectus supplement for primary offering
14 Oct 21
424B5
Prospectus supplement for primary offering
12 Oct 21
S-3ASR
Automatic shelf registration
12 Oct 21
Proxies
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
PRE 14A
Preliminary proxy
29 Mar 24
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
13 Apr 23
DEF 14A
Definitive proxy
29 Apr 22
PRE 14A
Preliminary proxy
15 Apr 22
DEFA14A
Additional proxy soliciting materials
16 Jun 21
DEFA14A
Additional proxy soliciting materials
27 May 21
DEF 14A
Definitive proxy
30 Apr 21
Other
EFFECT
Notice of effectiveness
16 Jun 20
CORRESP
Correspondence with SEC
11 Jun 20
UPLOAD
Letter from SEC
10 Jun 20
CT ORDER
Confidential treatment order
24 May 19
EFFECT
Notice of effectiveness
24 May 19
EFFECT
Notice of effectiveness
23 May 19
CERT
Certification of approval for exchange listing
22 May 19
CORRESP
Correspondence with SEC
20 May 19
CORRESP
Correspondence with SEC
20 May 19
CORRESP
Correspondence with SEC
20 May 19
Ownership
SC 13D
BAKER BROS. ADVISORS LP
18 Apr 24
3
JULIAN BAKER
18 Apr 24
4
Michael Charles Ferguson Hannay
12 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
4
Kevin Lee
5 Apr 24
4
Michael Skynner
5 Apr 24
4
Alistair Milnes
5 Apr 24
4
Nigel Crockett
5 Apr 24
4
Nicholas Keen
5 Apr 24
4
Travis Alvin Thompson
5 Apr 24